99P Cost effectiveness of pembrolizumab in combination with chemotherapy as neoadjuvant therapy and continued as a single agent as adjuvant therapy for high-risk early-stage TNBC in the United States
Titel:
99P Cost effectiveness of pembrolizumab in combination with chemotherapy as neoadjuvant therapy and continued as a single agent as adjuvant therapy for high-risk early-stage TNBC in the United States
Auteur:
Fasching, P.A. Huang, M. Haiderali, A. Xue, W. Pan, W. Zhou, Z-Y. Hu, P. Chaudhuri, M. Le Bailly De Tilleghem, C. Cappoen, N. O'Shaughnessy, J.